Treatment will proceed betting huge on Alan Wake and Management in 2026 after its first try at a self-published spinoff, FBC: Firebreak, did not set the world alight.
In its fiscal report for the 12 months ended December 31, 2025, the Finnish studio revealed Management has now offered over 5 million copies worldwide. That milestone was reached after the title generated 1 million gross sales in 2025.
In whole, the supernatural shooter has attracted over 20 million gamers since launching in August 2019 due to its inclusion on subscription providers like Xbox Sport Cross and PlayStation Plus—in addition to different partnerships.
Treatment advised traders it needs to capitalize on the success of Management by guaranteeing its recently-announced sequel, Management Resonant, is seen as a “must-have day-one buy” for followers of the unique.
“Launch-window is vital for a recreation’s business success, and we wish to seize the momentum,” reads the corporate’s earnings presentation. “We wish to have a spectacular product out on launch.”
The studio stated the announcement of Management Resonant at The Sport Awards in December 2025 supplied a “significant enhance” to gross sales of the unique. The sequel is at the moment slated to launch in 2026—although Treatment hasn’t confirmed a exact date or window.
Treatment welcomes ‘constructive and worthwhile’ fourth-quarter after troublesome 12 months
Discussing the efficiency of its different titles, Treatment stated Alan Wake 2 proceed to promote effectively whereas producing platform-deal royalties after being featured as a month-to-month recreation on PlayStation Plus in October 2025.
As for FBC: Firebreak, the underperforming multiplayer shooter self-published by Treatment, the corporate stated participant counts stay on a “steady however low stage.” The corporate will proceed supporting the title with “smaller updates” in 2026.
Elsewhere, the Max Payne 1 & 2 remake stays in full discount whereas a thriller ‘new undertaking’ has entered the proof-of-concept section.
So, how did Treatment finish what it conceded was a difficult 12 months? Interim CEO Markus Mäki, who might be changed by former EA exec Jean-Charles Gaudechon in March, defined This fall was “constructive and worthwhile.”
“Within the fourth quarter of 2025, Treatment’s income elevated by 46.3 p.c from the comparability interval and was €17.0 million. Sport gross sales and royalties saved on rising through the fourth quarter of 2025 and fashioned virtually half of the overall income for This fall 2025, the foremost contributors being royalties from Alan Wake 2 and recreation gross sales of Management,” he added.
“Improvement charges have been from Max Payne 1 & 2 remake and CONTROL Resonant. EBITDA was €3.9 million. Working revenue (EBIT) was €0.7 million. The advance in profitability within the fourth quarter was primarily pushed by the upper income stage in comparison with the comparability interval.”
Full-year income elevated by 17.5 p.c to €59.5 million, whereas EBITDA totalled €11.3 million. The corporate recorded an working lack of €14.9 million over the identical interval—a rise on the €4.3 million working loss recorded through the earlier fiscal 12 months.
Assessing the corporate’s long-term enterprise prospects, Maki stated Treatment stays dedicated to self-publishing its personal titles and evolving right into a “extremely regarded artistic studio with sustainable, important business success” by 2030.
Source link
#Management #topped #gross sales #attracted #20M #gamers
